BioMarin Q2 revenue rose 20% to $990 million; GAAP net income fell 81% to $45 million
BioMarin reported second-quarter 2026 total revenue of $990 million, up 20% from $825 million a year earlier, driven largely by the Amicus products acquired April 27, 2026. GAAP net income fell to $45 million from $241 million, mainly reflecting acquisition-related costs, intangible amortization and interest expense, and the company raised its full-year 2026 revenue and non-GAAP diluted EPS guidance.
Key points
- Q2 2026 GAAP diluted EPS was $0.23 versus $1.23 a year earlier; non-GAAP diluted EPS was $1.20 versus $1.44.
- Full-year 2026 total revenue guidance updated to $3,875 million to $3,925 million, from $3,825 million to $3,925 million previously.
- Full-year 2026 non-GAAP diluted EPS guidance raised to $4.90 to $5.10, from $4.85 to $5.05; VOXZOGO revenue guidance raised to $1,000 million to $1,050 million.
- Interest expense tied to the Amicus financing is estimated at approximately $200 million on an annualized basis.
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.